EHA 2024 – Shattuck reassurances fall on deaf ears
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.
The conference’s abstract drop features ASC4First in its plenary session.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.